Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

BACKGROUND: Cytokine fusion protein that modulates the immune response holds great potential for cancer immunotherapy. IL-2 is an effective treatment against advanced cancers. However, the therapeutic efficacy of IL-2 is limited by severe systemic toxicity. Several mutants recombinant IL-2 can incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mingjun, Wang, Haitao, Liu, Linjie, Wang, Bin, Sun, Guirong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888606/
https://www.ncbi.nlm.nih.gov/pubmed/27246873
http://dx.doi.org/10.1186/s12967-016-0910-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888606/
https://www.ncbi.nlm.nih.gov/pubmed/27246873
http://dx.doi.org/10.1186/s12967-016-0910-0

Ejemplares similares